# Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

> **NCT00820924** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 23 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** LAPATINIB

## Key facts

- **NCT ID:** NCT00820924
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820924, "Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00820924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*